UK Neuropsychiatric Disorders Treatment Market

ID: MRFR/HC/43511-HCR
200 Pages
Nidhi Mandole
Last Updated: April 06, 2026
UK Neuropsychiatric Disorders Treatment Market Research Report By Type (Degenerative Diseases, Neurotic Disorders, Psychosis, Others), By Application (Shock Treatment, Drug Treatment, Others) and By End User (Hospitals, Clinics, Research Centre’s, Others) - Growth & Industry Forecast 2025 To 2035
UK Neuropsychiatric Disorders Treatment Market
Market Size
Forecast Period2025 - 2035
CAGR (2025 - 2035)10.5%
2024 Market Size$ 5.45 Billion
2025 Market Size$ 6.02 Billion
2035 Market Size$ 16.35 Billion
Key Players
Johnson & Johnson
Pfizer
Eli Lilly and Company
AstraZeneca
Bristol-Myers Squibb
Novartis
Trends
  • Rise of Digital Therapeutics
  • Increased Focus on Preventive Care
  • Integration of Multidisciplinary Approaches
Opportunities
  • Rising Demand for Personalized Medicine
  • Advancements in Pharmacological Treatments
  • Growing Prevalence of Mental Health Disorders
Summary Table of Contents Segmentation Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. 1.1 EXECUTIVE SUMMARY
      1. 1.1.1 Market Overview
      2. 1.1.2 Key Findings
      3. 1.1.3 Market Segmentation
      4. 1.1.4 Competitive Landscape
      5. 1.1.5 Challenges and Opportunities
      6. 1.1.6 Future Outlook
  2. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. 2.1 MARKET INTRODUCTION
      1. 2.1.1 Definition
      2. 2.1.2 Scope of the study
        1. 2.1.2.1 Research Objective
        2. 2.1.2.2 Assumption
        3. 2.1.2.3 Limitations
    2. 2.2 RESEARCH METHODOLOGY
      1. 2.2.1 Overview
      2. 2.2.2 Data Mining
      3. 2.2.3 Secondary Research
      4. 2.2.4 Primary Research
        1. 2.2.4.1 Primary Interviews and Information Gathering Process
        2. 2.2.4.2 Breakdown of Primary Respondents
      5. 2.2.5 Forecasting Model
      6. 2.2.6 Market Size Estimation
        1. 2.2.6.1 Bottom-Up Approach
        2. 2.2.6.2 Top-Down Approach
      7. 2.2.7 Data Triangulation
      8. 2.2.8 Validation
  3. 3 SECTION III: QUALITATIVE ANALYSIS
    1. 3.1 MARKET DYNAMICS
      1. 3.1.1 Overview
      2. 3.1.2 Drivers
      3. 3.1.3 Restraints
      4. 3.1.4 Opportunities
    2. 3.2 MARKET FACTOR ANALYSIS
      1. 3.2.1 Value chain Analysis
      2. 3.2.2 Porter's Five Forces Analysis
        1. 3.2.2.1 Bargaining Power of Suppliers
        2. 3.2.2.2 Bargaining Power of Buyers
        3. 3.2.2.3 Threat of New Entrants
        4. 3.2.2.4 Threat of Substitutes
        5. 3.2.2.5 Intensity of Rivalry
      3. 3.2.3 COVID-19 Impact Analysis
        1. 3.2.3.1 Market Impact Analysis
        2. 3.2.3.2 Regional Impact
        3. 3.2.3.3 Opportunity and Threat Analysis
  4. 4 SECTION IV: QUANTITATIVE ANALYSIS
    1. 4.1 Construction, BY Disorders (USD Billion)
      1. 4.1.1 Degenerative Diseases
      2. 4.1.2 Neurotic Disorders
      3. 4.1.3 Psychosis
      4. 4.1.4 Others
    2. 4.2 Construction, BY Treatment (USD Billion)
      1. 4.2.1 Shock Treatment
      2. 4.2.2 Drug Treatment
      3. 4.2.3 Others
    3. 4.3 Construction, BY End User (USD Billion)
      1. 4.3.1 Hospitals
      2. 4.3.2 Clinics
      3. 4.3.3 Research Centres
      4. 4.3.4 Others
  5. 5 SECTION V: COMPETITIVE ANALYSIS
    1. 5.1 Competitive Landscape
      1. 5.1.1 Overview
      2. 5.1.2 Competitive Analysis
      3. 5.1.3 Market share Analysis
      4. 5.1.4 Major Growth Strategy in the Construction
      5. 5.1.5 Competitive Benchmarking
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Construction
      7. 5.1.7 Key developments and growth strategies
        1. 5.1.7.1 New Product Launch/Service Deployment
        2. 5.1.7.2 Merger & Acquisitions
        3. 5.1.7.3 Joint Ventures
      8. 5.1.8 Major Players Financial Matrix
        1. 5.1.8.1 Sales and Operating Income
        2. 5.1.8.2 Major Players R&D Expenditure. 2023
    2. 5.2 Company Profiles
      1. 5.2.1 Johnson & Johnson (US)
        1. 5.2.1.1 Financial Overview
        2. 5.2.1.2 Products Offered
        3. 5.2.1.3 Key Developments
        4. 5.2.1.4 SWOT Analysis
        5. 5.2.1.5 Key Strategies
      2. 5.2.2 Pfizer (US)
        1. 5.2.2.1 Financial Overview
        2. 5.2.2.2 Products Offered
        3. 5.2.2.3 Key Developments
        4. 5.2.2.4 SWOT Analysis
        5. 5.2.2.5 Key Strategies
      3. 5.2.3 Eli Lilly and Company (US)
        1. 5.2.3.1 Financial Overview
        2. 5.2.3.2 Products Offered
        3. 5.2.3.3 Key Developments
        4. 5.2.3.4 SWOT Analysis
        5. 5.2.3.5 Key Strategies
      4. 5.2.4 AstraZeneca (GB)
        1. 5.2.4.1 Financial Overview
        2. 5.2.4.2 Products Offered
        3. 5.2.4.3 Key Developments
        4. 5.2.4.4 SWOT Analysis
        5. 5.2.4.5 Key Strategies
      5. 5.2.5 Bristol-Myers Squibb (US)
        1. 5.2.5.1 Financial Overview
        2. 5.2.5.2 Products Offered
        3. 5.2.5.3 Key Developments
        4. 5.2.5.4 SWOT Analysis
        5. 5.2.5.5 Key Strategies
      6. 5.2.6 Novartis (CH)
        1. 5.2.6.1 Financial Overview
        2. 5.2.6.2 Products Offered
        3. 5.2.6.3 Key Developments
        4. 5.2.6.4 SWOT Analysis
        5. 5.2.6.5 Key Strategies
      7. 5.2.7 Sanofi (FR)
        1. 5.2.7.1 Financial Overview
        2. 5.2.7.2 Products Offered
        3. 5.2.7.3 Key Developments
        4. 5.2.7.4 SWOT Analysis
        5. 5.2.7.5 Key Strategies
      8. 5.2.8 Roche (CH)
        1. 5.2.8.1 Financial Overview
        2. 5.2.8.2 Products Offered
        3. 5.2.8.3 Key Developments
        4. 5.2.8.4 SWOT Analysis
        5. 5.2.8.5 Key Strategies
      9. 5.2.9 Otsuka Pharmaceutical (JP)
        1. 5.2.9.1 Financial Overview
        2. 5.2.9.2 Products Offered
        3. 5.2.9.3 Key Developments
        4. 5.2.9.4 SWOT Analysis
        5. 5.2.9.5 Key Strategies
    3. 5.3 Appendix
      1. 5.3.1 References
      2. 5.3.2 Related Reports
  6. 6 LIST OF FIGURES
    1. 6.1 MARKET SYNOPSIS
    2. 6.2 UK MARKET ANALYSIS BY DISORDERS
    3. 6.3 UK MARKET ANALYSIS BY TREATMENT
    4. 6.4 UK MARKET ANALYSIS BY END USER
    5. 6.5 KEY BUYING CRITERIA OF CONSTRUCTION
    6. 6.6 RESEARCH PROCESS OF MRFR
    7. 6.7 DRO ANALYSIS OF CONSTRUCTION
    8. 6.8 DRIVERS IMPACT ANALYSIS: CONSTRUCTION
    9. 6.9 RESTRAINTS IMPACT ANALYSIS: CONSTRUCTION
    10. 6.10 SUPPLY / VALUE CHAIN: CONSTRUCTION
    11. 6.11 CONSTRUCTION, BY DISORDERS, 2024 (% SHARE)
    12. 6.12 CONSTRUCTION, BY DISORDERS, 2024 TO 2035 (USD Billion)
    13. 6.13 CONSTRUCTION, BY TREATMENT, 2024 (% SHARE)
    14. 6.14 CONSTRUCTION, BY TREATMENT, 2024 TO 2035 (USD Billion)
    15. 6.15 CONSTRUCTION, BY END USER, 2024 (% SHARE)
    16. 6.16 CONSTRUCTION, BY END USER, 2024 TO 2035 (USD Billion)
    17. 6.17 BENCHMARKING OF MAJOR COMPETITORS
  7. 7 LIST OF TABLES
    1. 7.1 LIST OF ASSUMPTIONS
  8. 7.1.1
    1. 7.2 UK MARKET SIZE ESTIMATES; FORECAST
      1. 7.2.1 BY DISORDERS, 2025-2035 (USD Billion)
      2. 7.2.2 BY TREATMENT, 2025-2035 (USD Billion)
      3. 7.2.3 BY END USER, 2025-2035 (USD Billion)
    2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  9. 7.3.1
    1. 7.4 ACQUISITION/PARTNERSHIP
  10. 7.4.1

UK Neuropsychiatric Disorders Treatment Market Segmentation

UK Neuropsychiatric Disorders Treatment Market By Disorders (USD Billion, 2025-2035)

  • Degenerative Diseases
  • Neurotic Disorders
  • Psychosis
  • Others

UK Neuropsychiatric Disorders Treatment Market By Treatment (USD Billion, 2025-2035)

  • Shock Treatment
  • Drug Treatment
  • Others

UK Neuropsychiatric Disorders Treatment Market By End User (USD Billion, 2025-2035)

  • Hospitals
  • Clinics
  • Research Centres
  • Others

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories

Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.